Paper Title
Enhanced Anticancer Potential of Imipramine in Conjugation with Niacin in Dena Induced Hepatocellular Carcinoma

Abstract
Background Hepatocellular carcinoma (HCC) is constantly seeking the interest of researchers as an untreatable and fatal diseases attaining second position so far worldwide. Our study give us an opportunity to explore the new potential combinations in this regards. It is hypothesised that Imipramine anticancer activity which is used as an antidepressant drug can be potentiated with a adjuvant Niacin providing a better treatment approach. Methods A total of 40 animals were procured. After one week of aclimitization period animals were divided into eight groups (n=5 in each) such as Normal control, Disease (DENA) control, Imipramine control, Niacin control and Therapeutic groups as DENA + Imipramine control, DENA + Niacin and DENA + Imipramine + Niacin control and multivariable analysis was carried out to identify the most important contributing factors. Result Significant results were obtained in alteration of, Liver function test (p<0.001) , Tumor growth, Survival of Animals and Histopathology. The comparison was made between Disease Control and various Therapeutic groups DENA+ Imipramine (p<0.001), DENA+ Niacin (p<0.01), DENA+ Imipramine + Niacin (p<0.001). Interestingly DENA + Imipramine + Niacin combination showed a remarkable restoration in all liver enzymes along with histological reparative changes observed in the therapeutic groups. Conclusion Results deciphered an idea regarding a new approach of introducing a combination therapy such as Imipramine an anticancer drug whose potency is further ameliorated by an adjuvant Niacin therapy in conjugation. Keywords - DENA, Imipramine, Niacin, Liver Enzymes, Survival Rates.